Advanced search
Publication Cover
Emerging Drugs Volume 6, 2001 - Issue 1
Journal homepage
23
Views
4
CrossRef citations to date
0
Altmetric
Review

The effect of HMG-CoA reductase inhibitors on chronic allograft rejection

Terry Jones The Queen Elizabeth Hospital, Woodville, South Australia 5011, Australia. [email protected]
Pages 95-109 | Published online: 24 Feb 2005

Bibliography

  • SHEPHERD J, COBBE M, FORD I, et al. FOR THE WEST OFSCOTLAND CORONARY PREVENTION STUDY GROUP: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl. J. Med. (1995) 333:1301–1307.
  • SCANDINAVIAN SIMVASTATIN SURVIVAL STUDYGROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandi-navian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
  • •The first trial to report reduction in mortality following use of statins.
  • VAUGHAN CJ, MURPHY MB, BUCKLEY BM: Statins do more than just lower cholesterol. Lancet (1996) 348:1079–1082.
  • SUMI S, BEAUCHAMP D, TOWNSEND CM, et al.: Inhibition of pancreatic adencarcinoma cell growth by lovastatin. Gastroenterology (1992) 103:982–989.
  • •Study showing that statins exert anticancer activity via non-cholesterol lowering means.
  • WHEELER DC: Statins and the kidney. Curr. Opin. Nephrol. Hypertens. (1998) 7:579–584.
  • WIERZBICKI AS: The role of lipid lowering in transplan-tation. Int. J. Gun. Pract. (1999) 53:54–59.
  • VAUGHAN CJ, DELANTY N: Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke (1999) 30:1969–1973.
  • RAITERI M, ARNABOLDI L, MCGEADY P, et al.: Pharma-cological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp. Therap. (1997) 281:1144–1153.
  • NIELD G: Statins for all. Transplantation (2000) 69:1767–1768.
  • WADA H, MORI Y, KANEKO T, et al.: Elevated plasmalevels of vascular endothelial cell markers in patients with hypercholesterolaemia. Am. J Haematol (1993) 44:112–116.
  • AOKI I, AOKI N, KAWANO K, et al: Platelet-dependentthrombin generation in patients with hyperlipidae-mia. j Am. Coll. Cardiol. (1997) 30:91–96.
  • HOLSCHERMANN H, HILGENDORFF A, KEMKES-MATTHES B, et al.: Simvastatin attenuates vascular hypercoag-ulability in cardiac transplant recipients. Transplantation (2000) 69:1830–1836.
  • KATZNELSON S, WILKINSON AH, KOBASHIGAWA JA, et al.: The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation (1996) 61 :1469–1474.
  • ••A small trial demonstrating reduced cytotoxicity of naturalkiller cells post-kidney transplant which was associated with less acute rejection.
  • KOBASHIGAWA JA, KATZNELSON S, LAKS H, et al.: Effect of pravastatin on outcomes after cardiac transplanta-tion. N Engl. J. Med. (1995) 333:621–627.
  • ••Randomised trial demonstrating reduced rejection andbetter 1-year survival post-cardiac transplantation resulting from pravastatin use.
  • KATZNELSON S, WANG XM, CHIA D, et al.: The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic Tlymphocyte activity in vitro. 1 Heart Lung Transplant. (1998) 17:335–340.
  • TUNCER M, SULEYMANLAR G, ERSOY FF, et al.: Comparison of the effects of simvastatin and pravas-tatin on acute rejection in renal transplant patients. Transplant. Proc. (2000) 32:622–625.
  • KAKKIS JL, KE B, DAWSON S, et al.: Pravastatin increases survival and inhibits natural killer cell enhancement factor in liver transplanted rats. 1 Surg. Res. (1997) 69:393–398.
  • RUDDICH SM, MONGINI PKA, PEREZ RV, et al.: HMG-CoA Reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplant. Proc. (1998) 30:992–995.
  • IKEDA U, SHIMADA K: Statins and monocytes. Lancet (1999) 353:2070.
  • ROSENSON RS, TANGNEY CC, CASEY LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet (1999) 353:983–984.
  • MAGGARD M, KE B, WANG T, et al.: Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation (1998) 65:149–155.
  • MEISER BM, WENKE K, THIERY J, et al.: Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant. Proc. (1993) 25:2077–2079.
  • WENKE K, MEISER B, THIERY J, et al.: Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation (1997) 96:1398–1402.
  • ROMANO M, DIOMEDE L, SIRONI M, et al.: Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. (2000) 80:1095–1100.
  • CHAN KA, ANDRADE SE, BOLES M, et al.: Inhibitors ofhydroxymethylgutaryl-coenzyme A reductase and risk of fracture among older women. Lancet (2000) 355:2185–2188.
  • EDWARDS CJ, HART DJ, SPECTOR TD: Oral statins andincreased bone-mineral density in post menopausal women. Lancet (2000) 355:2218–2219.
  • O'DONNELL MP, KARISKE BL, KIM Y, et al.: Lovastatin inhibits proliferation of rat mesangial cells. J. Clin. Invest. (1993) 91:83–87.
  • DIMITROULAKOS J, NOHYNEK D, BACKWAY KL, et al.: Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood (1999) 93:1308–1318.
  • AXEL DI, RIESSEN R, RUNGE H, et al.: Effects of cerivas-tatin on human arterial smooth muscle proliferation and migration in transfilter cocultures. 1 Cardiovasc. Pharmacol. (2000) 35:619–629.
  • ENDRES M, LAUFS U, HUANG Z, et al.: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthetase. Proc. Natl. Acad. Sci. USA (1998) 95:8880–8885.
  • HAYRY P, AAVIK E, SAVOLAINEN H: Mechanisms of chronic rejection. Transplant. Proc. (1999) 31 (Suppl. 7A):5S–8S.
  • VARGHESE Z: Immunologic and nonimmunologic correlates of chronic renal allograft dysfunction. Transplant. Proc. (1999) 31 :3356–3358.
  • ALMOND PS, MATAS A, GILLINGHAM K, et al.: Risk factors for chronic rejection in renal allograft recipients. Transplantation (1993) 55:752–757.
  • MONACO AP, BURKE JF, FERGUSON RM, et al.: Current thinking on chronic renal allograft rejection: issues, concerns and recommendations from a 1997 roundtable discussion. Am. J. Kidney Dis. (1997) 33:150–160.
  • PONTICELLI C: Progression of renal damage in chronic rejection. Kidney Int. (2000) 57:62S–70S.
  • JAIN S, FURNESS PN, NICHOLSON M: The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation (2000) 69:1759–1766.
  • MEHRA MR, VENTURA HO, JAIN SP, et al: Heterogeneityof cardiac allograft vasculopathy: clinical insights from coronary angiography. j. Am. Coll. Cardiol. (1997) 29:1339–1344.
  • MULDOON MF, FLORY JD, MARSLAND AMS, et al.: Effects of lovastatin on the immune system. AM. J Cardiol (1997) 80:1391–1394.
  • DALEN JE, DALTON WS: Does cholesterol lowering cause cancer JAMA (1996) 275:67–69.
  • LAW MR, THOMPSON SG, WALD NJ: Assessing possible hazards of reducing serum cholesterol. Br. Med. J. (1994) 308:373–379.
  • BLAIS L, DESGAGNE A, LELORIER J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch. Intern. Med. (2000) 160:2363–2368.
  • CUTTS JL, BANKHURST AD: Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2.j Cell. Physiol. (1990) 145:244–252.
  • •Study showing lovastatin effect on natural killer cell activity is reversed by IL-2.
  • AKHLAGHI F, MCLACHLAN A, KEOGH A, et al: Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipi-ents. Br. J. Clin. Pharmacol (1997) 44:537–542.
  • Council of Europe Newsletter. Transplant (2000) 5.
  • JARDINE A, HOLDAAS H: Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J. Gun. Pharm. Therap. (1999) 24:397–408.
  • ONG CS, POLLOCK CA, CATERSON RJ, et al.: Hyperlipi-daemia in renal transplant recipients: natural history and response to treatment. Medicine (1994) 73:215–223.
  • HANES DS, NICHOLSON PG, RAVAL DD, et al.: A crossover comparison of the efficacy and safety oflovastatin and gemfibrozil in the treatment of hyperlipidaemic organ transplant recipients. Am. J. Therap. (1997) 4:85–91.
  • Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL (Eds.), McGraw-Hill, New York, USA (1998):1298–1300.
  • JAEGER BR, MEISER B, NAGEL D, et al.: Aggressive lowering of fibrinogen and cholesterol in the preven-tion of graft vessel disease after heart transplantation. Circulation (1997) 96 (Suppl. 2):154–158.
  • VALENTINE-VON KAEPPLER HA: Prevention of chronicheart allograft rejection. Transplant. Proc. (1999) 31:1288–1289.
  • KEOGH AM: Coronary artery disease in cardiac transplant recipients. Med. J Aust. (1995) 163:212–214.
  • KEOGH AM, VALANTINE HA, HUNT SA, et al.: Impact of proximal or midvessel discrete coronary artery stenosis on survival after heart transplantation. J Heart Lung Transplant. (1992) 11:892–901.
  • PATEL VS, LIM M, MASSIN EK, et al: Sudden cardiac death in cardiac transplant recipients. Circulation (1996) 94 (Suppl. 9):I1273–277.
  • HUSSEIN O, SCHLEZINGER S, ROSENBLAT M, et al.:Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis (1997) 128:11–18.
  • WITZUM JL: The oxidation hypothesis of atheroscle- rosis. Lancet (1994) 344:793–795.
  • •Review of role of LDL in atherosclerosis.
  • KATZNELSON S: The effect of HMG Co A reductase inhibitors on chronic allograft rejection. Contrib. Nephrol. (1997) 120:97–104.
  • CHRISTIANS U, JACOBSEN W, FLOREN LC: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are statins mechanistically similar Pharmacol. Ther. (1998) 80:1–34.
  • ••Extensive review of statins including potential for interac-tions, physical properties and metabolic fates.
  • WHITE MC: Pharmacological effects of HMG Co A reductase inhibitors other than lipoprotein modula-tion. J. Clin. Pharmacol. (1999) 39:111–118.
  • •Review of non-cholesterol lowering effects of statins.
  • IMAGAWA DK, DAWSON S, HOLT CD, et al.: Hyperlipi- daemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor - pravastatin. Transplantation (1996) 62:934–942.
  • KESTEN S, MAYNE L, SCAVUZZO M, et al.: lack of left ventricular dysfunction associated with sustained exposure to hyperlipidaemia following lung transplantation. Chest (1997) 112:931–936.
  • OPELZ G (FOR THE COLLABORATIVE TRANSPLANT STUDY): Effect of immunosuppressive therapy on graft half-life projections. Transplant. Proc. (1999) 31 (Suppl. 7A):315–335.
  • SPENCER CM, GOA KL, GILLIS JC: Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs (1997) 54:925–975.
  • GLOVER MT, DEEKS JJ, RAFTERY MJ, et al.: Irnmun 0 sup-pression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet (1997) 349:398.
  • Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL (Eds.), McGraw-Hill, New York, USA (1998):1520–1529.
  • SWINNEN LJ, COSTANZO-NORDIN MR, FISHER SG, et al.:Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody 0K13 in cardiac transplant recipients. N Engl. J. Med. (1990) 323:1723–1728.
  • KEOGH A, SPRATT P, MCCOSKER C, et al.: Ketoconazoleto reduce the need for cyclosporine after cardiac transplantation. N Engl. J. Med. (1995) 333:628–633.
  • FIRST MR, SCHROEDER TJ, MICHELA A, et al.:Cyclosporine-ketoconazole interaction. Long term follow up and preliminary results of a randomized trial. Transplantation (1993) 55:1000–1004.
  • CHRYSOSTOMOU A, WALKER RG, RUSS GR, et al.: Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation (1993) 55(2)300–304.
  • JONES TE: Survey of cyclosporin-sparing agent use inAustralasian transplant centres. Aust. NZ J. Med. (1996) 26:772–776.
  • HARWOOD HJ, HAMANAKA ES: Modulators of dyslipi-daemia. Emerging Drugs (1998) 3:147–172.
  • GRUER PJK, VEGA JM, MERCURI MF, et al.: Concomitant use of cytochrome P4503A4 inhibitors and simvas-tatin. Am. J. Cardiol (1999) 84:811–815.
  • •Summary of clinical data on interaction between simvas-tatin/pravastatin and CYP3A4 inhibitors including cyclosporin.
  • JONES TE: The use of other drugs to allow a lower dosage of cyclosporin to be used. Clin. Pharmacolcinel (1997) 32:357–367.
  • RUSCHITZKA F, METER PJ, TURINA M, et al.: Acute heart transplant rejection due to StJohn's Wort. Lancet (2000) 355:548–9.
  • GULLESTAD L, NORDAL KJ, BERG H, et al: Interactionbetween lovastatin and cyclosporine a after heart and kidney transplantation. Transplant. Proc. (1999) 31:2163–2165.
  • BALLANTYNE CM: Statins after cardiac transplantation: which statin, what dose and how low should we go Heart Lung Transplant. (2000) 19:515–517.
  • CORPIER CL, JONES PH, SUKI WN, et al.: Rhabdomyolysis and renal injury with Lovastatin use: report of two cases in cardiac transplant recipients. JAMA (1988) 260:239–241.
  • •First case reports of rhabdomyolysis due to interaction between cyclosporin and statins.
  • NORMAN DJ, ILLINGWORTH DR, MUNSON J, et al.: Myolysis and acute renal failure in a heart transplant recipient receiving lovastatin. N Engl. J Med. (1988) 318:46–47.
  • EAST C, ALIVATSOS PA, GRUNDY SM, et al.: Rhabdomy-olysis in patients receiving lovastatin after cardiac transplantation. N Engl. J. Merl. (1988) 318:47–48.
  • TOBERT JA: Letter to editor. N Engl. J. Merl. (1988) 31 8:48.
  • CELIK A, UNSAL A, MUTAF I, et al.: Which dosage of simvastatin in renal transplant recipients Nephron (2000) 84:81–82.
  • KEOGH A, MACDONALD P, KAAN A, et al.: Efficacy and safety of pravastatin vs. simvastatin after cardiac transplantation. J. Heart Lung Transplant. (2000) 19:529–537.
  • KILEY DJ, LAM CS, POLLAK R: A study of treatment compliance following kidney transplantation. Transplantation (1993) 55(1):51–56.
  • LILJA JJ, KIVISTO KT, NEUVONEN PJ: Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol Ther. (1999) 66:118–127.
  • WACHER VJ, WU CY, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A4 and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. (1995) 13:129–134.
  • SONNEVELD P, SCHOESTER M, DE LEEUW K: Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumour cells. J. Clin. Oncol. (1994) 12:1584–1591.
  • LOWN KS, MAYO RR, LEICHTMAN AB, et al.: Role of intestinal P-glycoprotein (mdrl) in in terp atient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. (1997) 62:248–260.
  • MUCK W, MAT I, FRITSCHE L, et al.: Increase in cerivas-tatin exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Therap. (1999) 65:251–261.
  • REUTER CWM, MORGAN MA, BERGMANN L: Targeting the Ras signalling pathway: a rational, mechanism-based treatment for hematoligic malignancies. Blood (2000) 96:1655–1669.
  • •Review of importance of Ras in cell signalling and why farnesylation inhibitors may be useful anticancer agents.
  • TAHIR SK, GU WZ, ZHANG HC, et al.: Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue. Eur. J Cancer (2000) 36:1161–1170.
  • EUMMER JT, GIBBS BS, ZAHN TJ, et al.: Novel limonene phosphonate and farnesyl diphosphate analogues: design, synthesis and evaluation as potential protein-farnesyl transferase inhibitors. Bioorg. Med. Chem. (1999) 7:241–250.
  • WET X, ST MS, IMAGAWA DK, et al.: Perrilyl alcohol inhibits TCR-mediated [Ca++] signalling, alters cell shape and motility and induces ap op tosis in T lymphocytes. Cell. Immunol. (2000) 201:6–13.
  • UNLU S, MASON CD, SCHACHTER M, et al.: Perillyl alcohol, an inhibitor of geranylgeranyl transferase, induces apoptosis of immortalised human vascular smooth muscle cells in vitro. J. Cardiovasc. Pharmacol (2000) 5:341–344.
  • ST MS, IMAGAWA DK, WET X, et al.: Mechanism of perillyl alcohol induced immunosuppression as anew class of immunosuppressive agents. Am. Soc. Transpl. Surg. (2000) Abstract.
  • •First report of usefulness of perillyl alcohol as immunosup-pressant for organ transplantation.

Websites

  • www.americanheart.org American Heart Association website data.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.